Skip to main content

Table 1 Baseline characteristics of studies included in the network meta-analysis of patients with cancer (NG = not given, pfu = plaque-forming units, TCID = tissue culture infective dose)

From: Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis

Study

(Phase, ID)

Study centres(No)

Sample size (No);

median age

Sex (male/female,%)

Study objective

Virus species

Group

Intervention

(arm 1/arm 2/arm 3/arm 4)

Moehler et al. [13] (II, NCT01387555)

38

86/43;NG

81.4/18.6

Advanced hepatocellular carcinoma

Vaccinia

Pexa-Vec 1 * 109 pfu/best supportive care

Noonan et al. [14] (II, NCT01280058)

6

36/37;64

56.2/43.8

Recurrent or metastatic pancreatic cancer

Reovirus

Pelareorep 3 * 1010 TCID 50 plus paclitaxel or carboplatin/paclitaxel or carboplatin

Gedeon et al. [15]

(II, NCT01199263)

36

54/54;NG

0/100.0

Recurrent or persistent ovarian epithelial, fallopian tube, or primary peritoneal cancer

Reovirus

Paclitaxel/p

pelareorep 3 * 1010 TCID 50 plus paclitaxel

Heo et al. [16] (II, NCT00554372)

9

14/16;64.9

76.7/23.3

Unresectable primary hepatocellular carcinoma

Vaccinia

Pexa-Vec 1 * 108 pfu/Pexa-Vec 1 * 109 pfu

Bernstein et al. [17] (II, NCT01656538)

7

36/38;NG

0/100.0

Metastatic breast cancer

Reovirus

Pelareorep 3 * 1010 TCID 50 plus paclitaxel/paclitaxel

Bradbury et al. [18] (II, NCT01708993)

12

38/37/39/38;NG

50.7/49.3

Advanced or metastatic non-small-cell lung cancer

Reovirus

Pelareorep 4.5 * 1010 TCID 50 plus pemetrexed/pemetrexed/pelareorep 4.5 * 1010 TCID 50 plus docetaxel/docetaxel

Chesney et al. [19] (II, NCT01740297)

40

98/100;NG

57.6/42.4

Advanced unresectable melanoma

Herpes simplex

T-VEC 1 * 106 pfu/1 * 108 pfu plus ipilimumab/ipilimumab

Eigl et al. [20] (II, NCT01619813)

11

41/44; 69

NG

Metastatic castration resistant prostate cancer

Reovirus

Pelareorep 3 * 1010 TCID 50 plus docetaxel/docetaxel

Jonker et al. [21] (II, NCT01622543)

10

51/52;60

61.2/38.8

Metastatic colorectal cancer

Reovirus

Pelareorep 3 * 1010 TCID 50 plus FOLFOX6 or bevacizumab/FOLFOX6 or bevacizumab

Andtbacka et al. [22] (III, NCT00769704)

83

295/141;63.1

57.2/42.8

Unresectable melanoma

Herpes simplex

T-VEC 1 * 106 pfu/1 * 108 pfu/GM-CSF 125 μg/m2/day

Schenk et al. [23] (II, NCT01017601)

196

26/24;63

48.0/52.0

Extensive-stage small cell lung cancer

Seneca valley virus

NTX-010 1 * 1011 (viral particles/kg)/placebo

PHOCUS [24] (III, NCT02562755)

142

234/225;60.9

84.1/15.9

Advanced hepatocellular carcinoma

Vaccinia

Pexa-Vec 1 * 109 pfu plus sorafenib/sorafenib

Burke et al. [25] (II, NCT01394939)

11

25/17;58.9

40.0/60.0

Metastatic, refractory colorectal carcinoma

Vaccinia

Pexa-Vec 1 * 109 pfu/Pexa-Vec 1 * 109 pfu plus irinotecan